Dexlansoprazole MR for the management of gastroesophageal reflux disease

References

• Sandler RS, Everhart JE, Donowitz M et al. The burden of selected digestive diseases in the United States. Gastroenterology122, 1500–1511 (2002).
   PubMed Web of Science ®Google Scholar
• DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am. J. Gastroenterol.100, 190–200 (2005).
   PubMed Web of Science ®Google Scholar
• Kahrilas PJ, Shaheen NJ, Vaezi MF et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology134, 1383–1391 (2008).
   Google Scholar
• Olsen KM, Hitzeman ML. Dexlansoprazole MR in the management of gastroesophageal reflux disease. Clin. Med. Ther.1, 1641–1652 (2009).
   Google Scholar
• Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single-release proton pump inhibitor therapy. Aliment. Pharmacol. Ther.29, 928–937 (2009).
   PubMed Web of Science ®Google Scholar
• Vakily M, Zhang W, Wu J, Atkinson SN, Mulford D. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials. Curr. Med. Res. Opin.25, 627–638 (2009).
   PubMed Web of Science ®Google Scholar
• Morelli G, Chen H, Rossiter G, Rege B, Lu Y. An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers. Aliment. Pharmacol. Ther.33(7), 845–854 (2011).
   PubMed Web of Science ®Google Scholar
• Laine L, Katz PO, Johnson DA et al. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis – the results of two double-blind studies. Aliment. Pharmacol. Ther.33, 203–212 (2011).
   PubMed Web of Science ®Google Scholar
• Abel C, Desilets AR, Willett K. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease. Ann. Pharmacother.44, 871–877 (2010).
   PubMedGoogle Scholar
• Fass R, Chey WD, Zakko SF et al. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment. Pharmacol. Ther.29, 1261–1272 (2009).
   PubMed Web of Science ®Google Scholar
• Metz DC, Howden CW, Perez MC et al. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Aliment. Pharmacol. Ther.29, 742–754 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang W, Wu J, Atkinson S. Pharmacokinetic (PK), pharmacodynamic(PD), and safety evaulation of single and multiple 60 mg, 90 mg, and 120 mg oral doses of modified release TAK-390 (TAK-390MR) and 30 mg oral doses of lansoprazole (Lan) in healthy subjects. Gastroenterology132(4 Suppl. 2), 487 (2007).
   Web of Science ®Google Scholar
• Wittbrodt ET, Baum C, Peura DA. Delayed release dexlansoprazole in the treatment of GERD and erosive esophagitis. Clin. Exp. Gastroenterol.2, 117–128 (2009).
   PubMedGoogle Scholar
• Dexilant ™ (dexlansoprazole), package insert. Takeda Pharmaceuticals North America Inc., IL, USA.
   Google Scholar
• Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor – evidence for dosing flexibility. Aliment. Pharmacol. Ther.29, 824–833 (2009).
   PubMed Web of Science ®Google Scholar
• Lee RD, Mulford D, Wu J, Atkinson SN. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor. Aliment. Pharmacol. Ther.31, 1001–1011 (2010).
   PubMed Web of Science ®Google Scholar
• Mayer MD, Vakily M, Witt G, Mulford DJ. The pharmacokinetics of TAK-390MR 60 mg, a dual delayed release formulation of the proton pump inhibitor TAK-390, and lansoprazole 60 mg: a retrospective analysis [abstract]. Gastroenterology134(4 Suppl. 1), A176 (2008).
   Google Scholar
• Czerniak R, Vakily M, Wu J. TAK-390MR, a novel dual delayed release formulation of a PPI, is bioequivalent when administered as granules sprinkled on applesauce. Am. J. Gastroenterol.103(Suppl. S), S4–S5 (2008).
   Web of Science ®Google Scholar
• Vakily M, Lee RD, Wu J, Gunawardhana L, Mulford D. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies. Clin. Drug Investig.29, 35–50 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin. Pharmacol. Ther.89(1), 65–74 (2011).
   PubMed Web of Science ®Google Scholar
• Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction?. Am. J. Gastroenterol.105, 34–41 (2010).
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Cryer BL, Contant CF et al. Clopidogrel with or without Omeprazole in coronary artery disease. N. Engl. J. Med.363, 1909–1917 (2010).
   PubMed Web of Science ®Google Scholar
• Paré G, Mehta SR, Yusuf S et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med.363, 1704–1714 (2010).
   PubMed Web of Science ®Google Scholar
• O’Donoghue ML, Braunwald E, Antman EM et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet374, 989–997 (2009).
   PubMed Web of Science ®Google Scholar
• Frelinger AL, Lee RD, Mulford DJ et al. A randomized, open-label, 2-period, crossover design study to assess the steady-state effects of dexlansoprazole, lansoprazole, esomeprazole or omeprazole on the pharmacokinetics and pharmacodynamics of clopidogrel in healthy subjects [abstract]. J. Am. Coll. Cardiol.57, E1098 (2011).
   Web of Science ®Google Scholar
• Frelinger AL, Bhatt DL, Lee RD et al. Clopidogrel pharmacokinetics and pharmacodynamics vary widely, independent of CYP2C19 polymorphisms, diet, smoking, proton pump inhibitors and other co-medications. J. Am. Coll. Cardiol.57, E927 (2011).
   Google Scholar
• Sharma P, Shaheen NJ, Perez MC et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation – results from two randomized controlled studies. Aliment. Pharmacol. Ther.29, 731–741 (2009).
   PubMed Web of Science ®Google Scholar
• Fass R, Johnson DA, Orr WC et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am. J. Gastroenterol.106(3), 421–431 (2011).
   PubMed Web of Science ®Google Scholar
• Howden CW, Larsen LM, Perez MC, Palmer R, Atkinson SN. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis – maintenance of healing and symptom relief. Aliment. Pharmacol. Ther.30, 895–907 (2009).
   PubMed Web of Science ®Google Scholar
• Peura DA, Metz DC, Dabholkar AH et al. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience. Aliment. Pharmacol. Ther.30, 1010–1021 (2009).
   PubMedGoogle Scholar
• Dabholkar AH, Han C, Paris MM et al. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther.33, 366–377 (2011).
   PubMedGoogle Scholar
• Metz DC, Vakily M, Dixit T, Mulford D. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single-release proton pump inhibitor therapy. Aliment. Pharmacol. Ther.29, 928–937 (2009).
   PubMed Web of Science ®Google Scholar